A peer-reviewed article, "Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device," written by Dr. Simon Allen and Prof. Ivan Aghajanyan has been published in the November 2015 issue of The Urology Journal, reports Fine Treatment. Their research demonstrates remarkable efficacy of Thermobalancing therapy and Dr Allen's Device for prostate enlargement.

Professor Ivan G. Aghajanyan, Head of the Department of Urology at The Mikaelyan Institute of Surgery, has conducted clinical studies on the use of Dr. Allen's Device and Thermobalancing therapy, and concludes that the efficacy of this new treatment method in defeating lower urinary tract symptoms (LUTS) and chronic prostatitis is amazing. The creation of this therapeutic approach is great news to enlarged prostate patients, as benign prostatic hyperplasia (BPH) is a common health problem for men over the age of 50.

In 2010, as many as 14 million men in the United States had lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Although BPH rarely causes symptoms before age 40, the occurrence and symptoms increase with age. BPH affects about 50% of men between the ages of 51 and 60 and up to 90% of men older than 80.

"Thermobalancing therapy is effective, and the therapeutic device is totally safe to use," comments Dr. Simon Allen. "We are pleased to be able to offer this harmless and effective method to BPH customers globally. The physiotherapeutic Dr Allen's Device provides a natural and effective treatment option for lower urinary tract symptoms, and should be prioritised over other treatment methods in cases of prostate enlargement as well as chronic prostatitis."

A clinically controlled trial involving 124 men with BPH, to whom the therapeutic device was administered exclusively as a mono-therapy, has confirmed the effectiveness and safety of Thermobalancing therapy. Thoroughly examined before and after a 6-month treatment period, the patients reported a significant improvement to the disturbing lower urinary tract symptoms (LUTS). Their treatment results compared favourably to other patients, also 124 men, in the control group.